{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:32:53Z","timestamp":1787070773284,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The clinical efficacy of adalimumab in treating severe plaque psoriasis is significant, but many questions and uncertainties remain. To evaluate the efficacy of adalimumab in treating patients with severe plaque psoriasis and to explore potential laboratory markers that may predict the efficacy of adalimumab. A retrospective analysis was conducted on 10 patients with severe plaque psoriasis who visited the dermatology department of our hospital from January 2020 to June 2024. Ten healthy individuals were included as a control group. Clinical scores of patients with severe plaque psoriasis were assessed, including body surface area (BSA), psoriasis area and severity index (PASI), and dermatology life quality index (DLQI). Cytokine levels in peripheral blood, including IL-2, IL-4, IL-6, IL-10, TNF-\u03b1, and IFN-\u03b3, were measured. Changes in clinical scores and cytokine levels before and 6 months after adalimumab treatment were compared. Additionally, changes in cytokine levels in peripheral blood were analysed for six patients with severe plaque psoriasis who experienced disease relapse. For patients with severe plaque psoriasis, BSA decreased from (18.10 \u00b1 4.89)% to (0.30 \u00b1 0.48)%, PASI score decreased from (18.79 \u00b1 4.91) to (0.12 \u00b1 0.19), and DLQI score decreased from (20.50 \u00b1 3.27) to (1.10 \u00b1 0.32) after 6 months of adalimumab treatment. IL-2 levels decreased from (9.18 \u00b1 4.26) pg\/mL to (1.35 \u00b1 1.36) pg\/mL, IL-4 from (2.45 \u00b1 1.25) pg\/mL to (0.36 \u00b1 0.41) pg\/mL, IL-6 from (11.91 \u00b1 6.38) pg\/mL to (1.61 \u00b1 1.07) pg\/mL, IL-10 from (5.28 \u00b1 2.10) pg\/mL to (1.86 \u00b1 0.92) pg\/mL, TNF-\u03b1 from (16.04 \u00b1 17.98) pg\/mL to (0.90 \u00b1 0.74) pg\/mL, and IFN-\u03b3 from (15.00 \u00b1 7.51) pg\/mL to (2.04 \u00b1 0.88) pg\/mL after 6 months of adalimumab treatment. Compared to the control group, the six cytokine levels in the peripheral blood of patients were significantly elevated before treatment and returned to normal levels after 6 months of treatment. During adalimumab treatment, a decrease in TNF-\u03b1 with a significant increase in IFN-\u03b3 in peripheral blood indicated potential reduced drug efficacy; no significant increase in TNF-\u03b1 and IFN-\u03b3 but an increase in IL-6 suggested the presence of other aggravating factors; significant increases in TNF-\u03b1, IFN-\u03b3, and IL-6 indicated possible treatment discontinuation. Adalimumab can improve clinical symptoms in patients with severe plaque psoriasis by antagonising TNF-\u03b1 and reducing levels of IL-2, IL-4, IL-6, IL-10, TNF-\u03b1, and IFN-\u03b3 in peripheral blood. Changes in peripheral blood levels of TNF-\u03b1, IFN-\u03b3, and IL-6 may serve as early indicators of adalimumab efficacy in treating severe plaque psoriasis.<\/jats:p>","DOI":"10.4103\/ijd.ijd_649_24","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T08:00:21Z","timestamp":1757750421000},"page":"363-370","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The Role of TNF - \u03b1, IFN - \u03b3, and IL-6 in Guiding Treatment and Predicting Prognosis in the Treatment of Severe Plaque Psoriasis with Adalimumab"],"prefix":"10.4103","volume":"70","author":[{"given":"Jian-Qing","family":"Zhang","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Shaoxing People\u2019s Hospital, Shaoxing, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Shaoxing People\u2019s Hospital, Shaoxing, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Shaoxing People\u2019s Hospital, Shaoxing, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Gang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory, Shaoxing People\u2019s Hospital, Shaoxing, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"R1-20251031","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.3390\/ijms20184347","article-title":"Risk factors for the development of psoriasis","volume":"20","author":"Kamiya","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R2-20251031","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R3-20251031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: Results from a phase 3, randomized, placebo-controlled, double-blind study","volume":"31","author":"Cai","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R4-20251031","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R5-20251031","doi-asserted-by":"crossref","first-page":"e13374","DOI":"10.1111\/dth.13374","article-title":"Efficacy and safety of adalimumab in difficult-to-treat psoriasis","volume":"33","author":"Lanna","year":"2020","journal-title":"Dermatol Ther"},{"key":"R6-20251031","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1358\/dot.2023.59.3.3419557","article-title":"Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis","volume":"59","author":"Simopoulou","year":"2023","journal-title":"Drugs Today Barc"},{"key":"R7-20251031","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris-Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R8-20251031","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris-Part 2: Specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"(Suppl 2)","key":"R9-20251031","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R10-20251031","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.det.2014.09.005","article-title":"Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice","volume":"33","author":"Chalmers","year":"2015","journal-title":"Dermatol Clin"},{"key":"R11-20251031","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-?) in autoimmune disease and current TNF-? inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R12-20251031","first-page":"97","article-title":"Current developments in the immunology of psoriasis","volume":"93","author":"Gr\u00e4n","year":"2020","journal-title":"Yale J Biol Med"},{"key":"R13-20251031","doi-asserted-by":"crossref","first-page":"108513","DOI":"10.1016\/j.clim.2020.108513","article-title":"Psoriatic arthritis under the influence of IFN?","volume":"218","author":"Dai","year":"2020","journal-title":"Clin Immunol"},{"key":"R14-20251031","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/jid.2011.458","article-title":"A single intradermal injection of IFN-? induces an inflammatory state in both non-lesional psoriatic and healthy skin","volume":"132","author":"Johnson-Huang","year":"2012","journal-title":"J Invest Dermatol"},{"key":"R15-20251031","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jaci.2018.08.048","article-title":"A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional skin from patients with psoriasis","volume":"143","author":"Gallais S\u00e9r\u00e9zal","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R16-20251031","first-page":"163","article-title":"Serum interferon-gamma is a psoriasis severity and prognostic marker","volume":"84","author":"Abdallah","year":"2009","journal-title":"Cutis"},{"key":"R17-20251031","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.4049\/jimmunol.181.7.4733","article-title":"Induction of IL-17+T cell trafficking and development by IFN-gamma: Mechanism and pathological relevance in psoriasis","volume":"181","author":"Kryczek","year":"2008","journal-title":"J Immunol"},{"key":"R18-20251031","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN?: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"R19-20251031","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jaci.2014.05.046","article-title":"Humanized anti-IFN-? (HuZAF) in the treatment of psoriasis","volume":"135","author":"Harden","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R20-20251031","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/jid.2008.194","article-title":"Psoriasis is characterized by accumulation of immunostimulatory and Th1\/Th17 cell-polarizing myeloid dendritic cells","volume":"129","author":"Zaba","year":"2009","journal-title":"J Invest Dermatol"},{"key":"R21-20251031","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol"},{"key":"R22-20251031","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/idoj.idoj_306_21","article-title":"Relevance of inflammatory cytokine mRNA expression of tumour necrosis factor- alpha (TNF ?), interleukin 17A (IL 17A) and interleukin 6 (IL 6) in Indian patients with psoriasis","volume":"13","author":"Shah","year":"2022","journal-title":"Indian Dermatol Online J"},{"key":"R23-20251031","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.abd.2023.03.002","article-title":"Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: A 6-year real-world cohort study","volume":"99","author":"Alves","year":"2024","journal-title":"An Bras Dermatol"}],"updated-by":[{"DOI":"10.4103\/ijd.ijd_986_25","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000}}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_649_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:36:21Z","timestamp":1787067381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_649_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_649_24","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2024-07-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}